Clinical Research Directory
Browse clinical research sites, groups, and studies.
Azithromycin for Child Survival in Niger II
Sponsor: University of California, San Francisco
Summary
Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR). The World Health Organization (WHO) guidelines for this intervention specify that implementation must be accompanied by continued monitoring of mortality and AMR. Niger is expanding the azithromycin MDA program nationwide. To establish monitoring of mortality and AMR as part of this program as well as to leverage the infrastructure to evaluate other child health interventions, AVENIR II is designed as an adaptive platform trial with monitoring and re-randomization every 2 years.
Official title: Azithromycine Pour la Vie Des Enfants au Niger II
Key Details
Gender
All
Age Range
1 Month - 59 Months
Study Type
INTERVENTIONAL
Enrollment
3300000
Start Date
2024-04-29
Completion Date
2028-04-29
Last Updated
2025-06-22
Healthy Volunteers
Yes
Conditions
Interventions
Azithromycin for Oral Suspension
Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
Locations (1)
Program National de Santé Oculaire
Niamey, Niger